Prognostic significance of systemic immune inflammation index for ovarian cancer: An updated systematic review and meta-analysis

Journal of Ovarian Research, Journal Year: 2025, Volume and Issue: 18(1)

Published: Feb. 27, 2025

Abstract Objective Several inflammatory indices have been used to assess the prognosis of ovarian cancer, with variable results. This review assessed whether systemic immune inflammation index (SII) can predict outcomes in patients cancer. Methods Embase, PubMed, CENTRAL, Web Science, and Scopus databases were searched by two reviewers from inception 15th October 2024 for studies assessing relationship between SII overall survival (OS) or disease-free (DFS). Results Ten eleven cohorts included. Pooled analysis showed that higher was a significant predictor poor OS (HR: 2.35 95% CI: 1.56, 3.55 I 2 = 88%) worse DFS 2.51 1.71, 3.67 80%) after Sensitivity failed change significance No publication bias noted. Most results remained on subgroup analyses based location, sample size, FIGO stage, treatment, adjusted outcomes, cut-off SII, method determining cut-off, quality score. Conclusions be potential Further are required improve evidence.

Language: Английский

---

Causal relationship and potential common pathogenic mechanisms between hidradenitis suppurativa and related cancer

Discover Oncology, Journal Year: 2025, Volume and Issue: 16(1)

Published: March 12, 2025

Hidradenitis suppurativa (HS) is a chronic, inflammatory and common skin disease. Observation studies have reported the association between HS cancers, however no whether causal relationship exists cancers. This study aimed to explore differential subtypes of cancers by conducting bidirectional Mendelian randomization (MR) analysis. Genome-wide (GWAS) data related 16 were collected. The inverse variance weighted (IVW) method was primarily applied for our MR analysis, MR-Egger, median, simple mode, mode methods used additionally. Heterogeneity, horizontal pleiotropy, potential outliers assessed analysis results. Subsequently, disease-related genes retrieved from GeneCards database. To investigate functions these associated genes, Gene Ontology (GO) Kyoto Encyclopedia Genes Genomes (KEGG) enrichment analyses conducted. results indicated pancreatic cancer (PAC). Specifically, found elevate risk developing PAC (odds ratio (OR), 1.074; 95% confidence interval (CI) 1.015–1.135; p = 0.013). Conversely, reverse demonstrated that does not exert effect on HS. Furthermore, findings did reveal any significant relationships other types cancer. No evidence heterogeneity or pleiotropy identified in Additionally, we subsequent GO KEGG both are implicated pathways with immune processes. this offer novel regarding HA PAC. Our indicates may influence PAC, which could inform development improved treatment strategies patients suffering However, underlying mechanisms warrant further exploration.

Language: Английский

---

Allergen Immunotherapy: Pitfalls, Perks and Unexpected Allies

International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(8), P. 3535 - 3535

Published: April 9, 2025

Allergen immunotherapy (AIT) is a well-established treatment aimed at reducing allergen sensitivity by gradually exposing the immune system to increasing doses of allergens. This promotes desensitization and tolerance through multiple mechanisms. AIT offers long-term modulation considered potentially curative certain forms allergic diseases. Altered antibody responses key mechanism in production allergen-specific IgG4 antibodies, which act as blocking antibodies prevent binding IgE on mast cells (MCs) basophils. However, are sometimes ineffective due variations affinity epitope targeting. Reverse class switching from selective depletion IgE-producing B represent potential strategies improve efficacy. Tregs play central role suppressing Th2-driven promoting anti-inflammatory cytokines interleukin (IL)-10 transforming growth factor (TGF)-β. genetic environmental factors may impair Treg function, leading failure. reduces MC basophil activation, suppression inflammation. It modulates IgE-FcεRI interactions cytokine signaling pathways, but some cases, anaphylactic reactions or resistance occur. Discussion conclusions: While highly effective allergy treatment, variability can impact its success. Advances biologic therapies offer synergies with AIT. Understanding these will help refine patient outcomes.

Language: Английский

---

Gut microbial metabolites targeting JUN in renal cell carcinoma via IL-17 signaling pathway: network pharmacology approach

Molecular Diversity, Journal Year: 2025, Volume and Issue: unknown

Published: April 18, 2025

Abstract The gut microbiome plays a crucial role in renal diseases, influencing conditions such as cell carcinoma (RCC), acute kidney injuries, and diabetic nephropathy. Recent studies highlight the association between microbial metabolites (GMM) RCC progression. This study employs computational network pharmacology framework to explore mechanistic action of microbiota-derived against RCC. GMM were selected from gutMgene database analyzed for common targets using DisGeNET, Gene Card, OMIM. Downstream analysis included gene ontology, KEGG pathway enrichment, metabolite-target-pathway-disease construction, protein–protein interaction analysis. Further, key evaluated drug-likeness, ADMET properties, molecular docking, followed by dynamics simulations (MDS) assess complex stability. JUN/AP-1 emerged prime target, exhibiting highest binding affinity with Icaritin (− 5.9 kcal/mol), Quercetin Luteolin. MDS confirmed stable active site throughout simulation. These may influence anticancer activity through distinct regulatory pathways involving gene, either inhibiting or modulating its function. insights establish basis further vitro vivo investigations, supporting development microbiome-based therapeutic approaches. Graphical abstract graphical illustrates computer-aided approach investigating (RCC). It highlights core target genes, pathways, analyses. right section depicts microbiota, specifically Bacterium sp. MRG-PMF-1 produces Icaritin, which inhibits JUN potentially suppressing Molecular docking confirm interactions, Icaritin’s potential.

Language: Английский

---

Regulatory factors of ILC2 are therapeutic targets for lung inflammation

iLABMED, Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 23, 2024

Abstract Type 2 innate lymphoid cells (ILC2s) are an important class of immune that play a key role in regulating responses, maintaining tissue homeostasis, and participating responses induced by inflammatory diseases. In lung inflammation, ILC2s drive the response secreting type cytokines, have significant repair maintenance barrier function IL‐9 antimicrobial peptides. activation affected various regulatory factors, including epithelial‐derived alarmins such as IL‐25, IL‐33, thymic stromal lymphopoietin, neurotransmitters, metabolites hormones. These factors affect development through signaling pathways under different pathological conditions. An in‐depth study is expected to provide new targets strategies for treatment inflammation.

Language: Английский

---

Allergen-specific immunotherapy at the extremes of age: below 5 years and elderly: evidence beyond indications?

Current Opinion in Allergy and Clinical Immunology, Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 20, 2024

Purpose of review Allergen-specific immunotherapy (AIT) has been used in clinical practice to treat allergic diseases for over 100 years. The effectiveness and safety AIT have substantiated numerous studies; however, children before 5 years age elderly are not encompassed generally. This aims present the current understanding extremes age. Recent findings Early allergen during infancy or early childhood may prevent development sensitization common allergens, thereby reducing risk developing later life. In elderly, improved symptoms quality life reduced dependence on medication indicated importance implementation AIT. Both immunological parameters demonstrated that treatment was effective at time cessation trend sustained tolerance. Summary There is no specific lower upper limit initiating immunotherapy; it important thoroughly evaluate severity disease risks benefits each case.

Language: Английский

---